<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04277767</url>
  </required_header>
  <id_info>
    <org_study_id>AD2020</org_study_id>
    <nct_id>NCT04277767</nct_id>
  </id_info>
  <brief_title>The Role of Ophthalmologic Tests and EEG Imaging in Alzheimer's Disease</brief_title>
  <official_title>The Combination of Ophthalmologic Tests and EEG Imaging as a New Biomarker for Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Ophthalmic Center, Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Ophthalmic Center, Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alzheimer's disease (AD) is a prevalent, long-term progressive degenerative disorder with
      great social impact. It is currently thought that, in addition to neurodegeneration, vascular
      changes also play a role in the pathophysiology of the disease. Meantime, EEG resting state
      has also demonstrated significant change in patients with AD in neuroscience research area.
      Thus, the combination of these sensitive biomarkers would lead to a potential new biomarker
      for detection of AD, which has higher specificity and sensitivity.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>OCT retinal and choroidal thickness</measure>
    <time_frame>2 days</time_frame>
    <description>retinal structural anatomy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Retinal Photography vascular caliber</measure>
    <time_frame>2 days</time_frame>
    <description>use Retinal Photography to detect vascular caliber</description>
  </primary_outcome>
  <primary_outcome>
    <measure>functional connection strength in the brain network</measure>
    <time_frame>7 days</time_frame>
    <description>record resting-state EEG, use graph theory to calculate the functional connection strength</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>mild cognitive impairment (MCI)</arm_group_label>
    <description>observational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with mild to moderate AD</arm_group_label>
    <description>observational</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal controls</arm_group_label>
    <description>observational</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>observational</intervention_name>
    <description>No intervention</description>
    <arm_group_label>Normal controls</arm_group_label>
    <arm_group_label>Patients with mild to moderate AD</arm_group_label>
    <arm_group_label>mild cognitive impairment (MCI)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        We would recruit three groups of elders. One is the control group without cognitive
        impairment, one is the aMCI group which is deemed as the pre-stage of AD, and also the AD
        group.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Alzheimer's Disease

        Exclusion Criteria:

          -  neurologic disorders

          -  psychiatric disorders
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Yuan, phD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmological Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jin Yuan, phD</last_name>
    <phone>13825141659</phone>
    <email>yuanjincornea@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Li Gu, phD</last_name>
    <phone>+8615889937313</phone>
    <email>guli7@mail2.sysu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhongshan Ophthalmic Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Li Gu, Dr.</last_name>
      <phone>15889937313</phone>
      <phone_ext>+86</phone_ext>
      <email>guli7@mail2.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jin yuan, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>January 13, 2020</study_first_submitted>
  <study_first_submitted_qc>February 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 20, 2020</study_first_posted>
  <last_update_submitted>May 16, 2020</last_update_submitted>
  <last_update_submitted_qc>May 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Jin Yuan</investigator_full_name>
    <investigator_title>assistant dean</investigator_title>
  </responsible_party>
  <keyword>AD EEG OCT biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

